ES2157309T3 - Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas. - Google Patents

Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas.

Info

Publication number
ES2157309T3
ES2157309T3 ES95810545T ES95810545T ES2157309T3 ES 2157309 T3 ES2157309 T3 ES 2157309T3 ES 95810545 T ES95810545 T ES 95810545T ES 95810545 T ES95810545 T ES 95810545T ES 2157309 T3 ES2157309 T3 ES 2157309T3
Authority
ES
Spain
Prior art keywords
radiomarcated
somatostatine
compositions
chelating groups
analogs containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95810545T
Other languages
English (en)
Inventor
Rainer Albert
Christian Bruns
Peter Smith-Jones
Barbara Stolz
Gisbert Weckbecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2157309T3 publication Critical patent/ES2157309T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C07K14/6555—Somatostatins at least 1 amino acid in D-form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE PRESENTAN COMPUESTOS DE LA FORMULA (I) EN LA QUE M ES UN EQUIVALENTE DE CATION Y A ES PHE O TYR, EN LA FORMA LIBRE O EN FORMA DE SAL, LOS COMPUESTOS SON UTILES COMO PRODUCTOS RADIOFARMACOLOGICOS CUANDO SE COMPLEJAN CON UN RADIONUCLEOTIDO EMISOR DE {AL} O DE {BE} O UN NUCLIDO CON CASCADAS DE E{SP,-} DE AUGER.
ES95810545T 1994-09-06 1995-09-04 Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas. Expired - Lifetime ES2157309T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9417873A GB9417873D0 (en) 1994-09-06 1994-09-06 Organic compounds

Publications (1)

Publication Number Publication Date
ES2157309T3 true ES2157309T3 (es) 2001-08-16

Family

ID=10760870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95810545T Expired - Lifetime ES2157309T3 (es) 1994-09-06 1995-09-04 Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas.

Country Status (31)

Country Link
US (2) US6183721B1 (es)
EP (1) EP0714911B1 (es)
JP (1) JP3054346B2 (es)
KR (1) KR100364111B1 (es)
CN (1) CN1185252C (es)
AT (1) ATE199561T1 (es)
AU (1) AU703057B2 (es)
BR (1) BR9503936A (es)
CA (1) CA2157530C (es)
CO (1) CO4410344A1 (es)
CZ (1) CZ287012B6 (es)
DE (1) DE69520256T2 (es)
DK (1) DK0714911T3 (es)
ES (1) ES2157309T3 (es)
FI (1) FI117424B (es)
GB (1) GB9417873D0 (es)
GR (1) GR3035997T3 (es)
HU (1) HU218284B (es)
IL (1) IL115154A (es)
NO (1) NO316569B1 (es)
NZ (1) NZ272919A (es)
PE (1) PE41496A1 (es)
PL (1) PL182434B1 (es)
PT (1) PT714911E (es)
RU (1) RU2156774C2 (es)
SG (1) SG50356A1 (es)
SI (1) SI0714911T1 (es)
SK (1) SK283774B6 (es)
TR (1) TR199501094A2 (es)
TW (1) TW387898B (es)
ZA (1) ZA957475B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
AT405906B (de) * 1997-03-14 1999-12-27 Irene Dr Virgolini Radiomarkierte somatostatin rezeptor-liganden zur diagnose und therapie
US6358491B1 (en) 1999-08-27 2002-03-19 Berlex Laboratories, Inc. Somatostatin analogs
EP2269603B1 (en) 2001-02-19 2015-05-20 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with exemestane
AU2002253999A1 (en) 2001-02-26 2002-09-12 Bristol-Myers Squibb Pharma Company Ascorbic acid analogs for metalloradiopharmaceuticals
ITMI20011708A1 (it) * 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
ES2443416T3 (es) 2002-07-18 2014-02-19 Helix Biopharma Corp. Uso de ureasa para inhibir el crecimiento de células cancerosas
JP2006522100A (ja) * 2003-03-10 2006-09-28 バイオジェン アイデック インク 標的化ペプチドに対するチオール媒介性薬物結合
KR101699142B1 (ko) 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
EP1831241A2 (en) * 2004-11-24 2007-09-12 AplaGen GmbH Method for solid-phase peptide synthesis and purification
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
CN103518135B (zh) 2011-03-11 2016-08-17 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
WO2014081655A1 (en) 2012-11-21 2014-05-30 Serene Oncology, Llc Tin-1 17m comprising somatostatin receptor binding compounds
CN103275189B (zh) * 2013-06-06 2014-08-06 深圳翰宇药业股份有限公司 一种用于肽树脂的裂解液及其在固相裂解合成生长抑素中的应用
PT3383920T (pt) 2015-11-30 2024-04-15 Univ California Entrega de carga útil específica para tumores e ativação imune utilizando um anticorpo humano que tem como alvo um antigénio altamente específico da superfície das células tumorais
WO2018044812A2 (en) 2016-08-29 2018-03-08 Fred Hutchinson Cancer Research Center Chelating platform for delivery of radionuclides
US12049511B2 (en) 2016-11-10 2024-07-30 Fortis Therapeutics, Inc. Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
AU2018207190B2 (en) 2017-01-12 2020-12-03 Orano Med Treatment of cancer cells overexpressing somatostatin receptors using ocreotide derivatives chelated to radioisotopes
TW202017600A (zh) * 2018-06-21 2020-05-16 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
TW202015744A (zh) * 2018-06-21 2020-05-01 法商艾普森藥品公司 用於放射性醫藥之含有體抑素類似物之組成物
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
US10596278B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN116419747A (zh) 2020-08-07 2023-07-11 福蒂斯治疗公司 靶向cd46的免疫偶联物及其使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006643A (en) 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
DE3728600A1 (de) 1987-08-27 1989-03-09 Hoechst Ag Verfahren zur markierung von substanzen mit technetium oder rhenium
ATE134999T1 (de) * 1988-05-25 1996-03-15 Us Commerce Makrocyclische chelate und verwendungsverfahren
GB9111199D0 (en) * 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
CA2066031C (en) 1989-09-29 2001-02-27 Mary A. Gray Methods for reducing non-target retention of immunoconjugates and metabolites thereof
EP0636032A1 (en) * 1992-03-25 1995-02-01 Mallinckrodt Medical, Inc. Method of intraoperatively detecting and locating tumoral tissues
EP0607103A3 (en) * 1993-01-12 1997-07-09 Sandoz Ltd Somatostatin analogs containing chelating groups and their radiolabeled compositions.
US5650134A (en) * 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
DE69526203T2 (de) * 1994-01-12 2002-11-28 Amersham Plc, Little Chalfont Biologische zielgerichtete mittel
GB9417873D0 (en) * 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
NO316569B1 (no) 2004-02-23
HUT72895A (en) 1996-06-28
ATE199561T1 (de) 2001-03-15
FI117424B (fi) 2006-10-13
AU3041495A (en) 1996-03-21
CA2157530A1 (en) 1996-03-07
KR960010683A (ko) 1996-04-20
CZ226395A3 (en) 1996-03-13
US6277356B1 (en) 2001-08-21
CN1127259A (zh) 1996-07-24
NZ272919A (en) 1996-12-20
US6183721B1 (en) 2001-02-06
JPH0881498A (ja) 1996-03-26
EP0714911A2 (en) 1996-06-05
PL310274A1 (en) 1996-03-18
PT714911E (pt) 2001-08-30
FI954147A (fi) 1996-03-07
PL182434B1 (pl) 2002-01-31
BR9503936A (pt) 1996-09-24
IL115154A0 (en) 1995-12-31
CZ287012B6 (en) 2000-08-16
HU9502577D0 (en) 1995-11-28
JP3054346B2 (ja) 2000-06-19
GR3035997T3 (en) 2001-09-28
SG50356A1 (en) 2000-11-21
DE69520256D1 (de) 2001-04-12
FI954147A0 (fi) 1995-09-04
CA2157530C (en) 2007-04-03
NO953457D0 (no) 1995-09-04
HU218284B (en) 2000-07-28
ZA957475B (en) 1997-03-06
GB9417873D0 (en) 1994-10-26
NO953457L (no) 1996-03-07
RU2156774C2 (ru) 2000-09-27
AU703057B2 (en) 1999-03-11
SK283774B6 (sk) 2004-01-08
TR199501094A2 (tr) 1996-06-21
KR100364111B1 (ko) 2003-02-05
CN1185252C (zh) 2005-01-19
IL115154A (en) 2000-08-13
SK108895A3 (en) 1996-06-05
CO4410344A1 (es) 1997-01-09
DK0714911T3 (da) 2001-07-09
SI0714911T1 (en) 2001-08-31
DE69520256T2 (de) 2001-08-09
EP0714911B1 (en) 2001-03-07
EP0714911A3 (en) 1996-08-21
PE41496A1 (es) 1996-10-14
TW387898B (en) 2000-04-21

Similar Documents

Publication Publication Date Title
ES2157309T3 (es) Analogos de somatostatina que contienen grupos quelantes y sus composiciones radiomarcadas.
MX156804A (es) Mejoras a composicion blanqueadora estabilizada que contiene enzimas
IT1170852B (it) Composizione imbiancante contenente perossido d'idrogeno
MY113732A (en) Arylthio compounds
DE69716461D1 (de) Antithrombotische organische nitrate
MX9101445A (es) Composiciones de organosilicio que contienen elastomeros hidrocarburo
BE887531A (fr) Nouvelles compositions d'etancheite
DE3784566D1 (de) Bisphenolverbindungen enthaltende zusammensetzungen.
ES2173661T3 (es) Agente de lavado liquidos de baja concentracion alatamente viscosos.
BR9610024A (pt) Pigmento anti-corrosivo e composições formuladas contendo tais pigmentos
JPS5618655A (en) Optically whitening agent mixture
MX163676B (es) Mejoras a resinas no gelificadas que contienen grupos hidrolizables de compuestos organosilano
FR2503538B1 (fr) Composition bactericide-bacteriostatique a usage industriel
FR2466792B1 (fr) Composition photopolymerisable contenant un compose de s-triazine
NO154754C (no) Stoepeasfaltblanding inneholdende syntetisk zeolitt.
DE3870954D1 (de) Zahnaerztliche haftmittelzusammensetzung.
HUT39725A (en) Solide herbicide compositions containing quaterner salts of bipiridinium
HK1004269A1 (en) Substituted saccharin compounds and curable compositions containing same
ES2066578T3 (es) Composicion detergente liquida concentrada que contiene un agente secuestrante de tipo polifosfonato.
IT1148192B (it) Composizioni flemmatizzate contenenti composti suscettibili di esplosione
DE3464598D1 (en) Acetylene derivatives having an enzyme-inhibiting activity, their preparation and their use as medicines
BE853617A (fr) Compositions de colle animale contenant des composes d'ammonium quaternaire
BE857354A (fr) Compositions antiarthritiques contenant des sels d'or (1+) bis-coordines
SE8605391D0 (sv) Forfaringssett for att skydda ett plantetningsarrangemang
GB8802045D0 (en) Improvements relating to curable compositions

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 714911

Country of ref document: ES